You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Commercialization of a Novel Therapeutic for Alzheimer's Disease
SBC: CoPlex Therapeutics, LLC Topic: NIAABSTRACT Traditional mon therapeutictarget driven approaches to drug development for Alzheimer s diseaseADare becoming increasingly expensive and in many cases disappointingly unsuccessfulBased on preliminary in vitro and in vivo studies we have identified a novel small moleculemethyldimethyloxodihydrobenzo cnaphthyridinecarboxylateBNCthat significantly decreases neuroinflammation and production o ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Personalized dosing of dichloroacetate for the treatment of rare and common diseases
SBC: Medosome Biotec, LLC Topic: NICHDPyruvate dehydrogenase complexPDCdeficiencyPDCDis a rare disease of mitochondrial energy failure in which the life of expectancy of affected children is severely truncatedTreatment of PDCD remains a seriousunmetchallengeThere has never been a controlled trial of any intervention for PDCDthusthere is no proven therapy for affected patientsDichloroacetateDCArepresents the first targeted therapy for ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Lentiviral Vector for the treatment of Fanconi Anemia
SBC: Rimedion, Inc. Topic: NHLBIDESCRIPTIONprovided by applicantIn this Phase II STTR application Rimedion seeks to commercialize a novel treatment for patients suffering from Fanconi anemia and request funding for a Phase I II clinical trialThe product will utilize a HIVbased lentiviral vector expressin the Fanconi anemia A proteinThe strong scientific support for this approached is strengthened by a successful Phase I STTRThe ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
SA FasL engineered human islets as a novel product for the treatment of type diabetes
SBC: FasCure Therapeutics LLC Topic: NIDDKPROJECT SUMMARY Type diabetes T D is a chronic autoimmune disorder that affects of population worldwide Exogenous insulin treatment is the standard of care for T D but often negatively affects the quality of life and is ineffective in preventing recurrent hyperglycemia episodes and chronic complications Recent studies show that human islet allografts can restore long term normoglycemia ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Novel Probiotic Platform to Treat Necrotizing Enterocolitis
SBC: MONON BIOVENTURES LLC Topic: 300PROJECT SUMMARY Probiotics hold enormous potential for promoting human health and treating disease One major hurdle to many probiotic products is their lack of persistence in the gut Monon Bioventures MBV and their research partners at the Research Institute at Nationwide Childrenandapos s Hospital RINCH are developing a novel enhanced tunable technology called ProNextTM that allows for a ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of CaSR nutrient therapy for childhood diarrhea
SBC: Medosome Biotec, LLC Topic: NICHDProject Abstract Acute infectious diarrhea is a worldwide problem especially among infants young children and immune compromised patients Sadly million children die each year not because of the infections causing diarrhea but due to the associated dehydration The pro absorptive Oral Rehydration Solution ORS is the only recommended oral therapy for children with acute diarrhea yet it ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines
SBC: VaxNewMO Topic: NIAIDPROJECT SUMMARY Pneumococcal pneumonia remains the leading cause of bacterial pneumonia in both children under years of age and adults over years of age The standard preventative therapy is the conjugate vaccine Prevnar which consists of an immunogenic carrier protein covalently attached to one of thirteen pneumococcal capsular polysaccharides Although Prevnar has significantly red ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Developing a Nutraceutical Product against Noise Induce Hearing Loss
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIDCDPROJECT SUMMARY The most common occupational and environmental hazard in this country is noise Itandapos s not surprising then that noise induced hearing loss NIHL is the second most common form of sensorineural hearing deficit behind only age related hearing loss presbycusis Although therapeutics that target the free radical pathway have shown promise for reducing NIHL there are no effe ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Rational design of small interfering RNA for genome-wide target knockdown
SBC: Nawgen, LLC Topic: 172DESCRIPTION provided by applicant RNA interference RNAi is a small RNA guided gene silencing process within living cells The RNAi technique is widely used in both biological research and clinical applications because it has the ability to knockdown essentially any gene of interest However one major unresolved issue in RNAi studies is non specific gene silencing It is well known that in ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
TheraBracelet: The first and only wearable to instantly improve stroke hand function
SBC: TheraBracelet, Inc. Topic: NICHDProject SummaryPost stroke hand impairment is highly prevalent and severely restricts functional ability and independenceIn facteveryseconds a new stroke occursand stroke is recognized as the leading cause of long term disabilityYetthere is no assistive device to help hand function at homeevery dayduring activities of daily livingExisting devices such as hand opening orthoses are expensivee gMyomo ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health